An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol

  • Cancer
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:


This trial runs in
  • A Coruña
  • Alexandria Governorate
  • Auckland
  • Banja Luka
  • Barcelona
  • Beograd
  • Boston
  • Bruxelles
  • Budapest
  • Cairo Governorate
  • Cape Town
  • Cartagena
  • Chicago
  • Christchurch
  • Cluj-Napoca
  • Daegu
  • Dakahlia Governorate
  • Dallas
  • Debrecen
  • Gharbia Governorate
  • Glasgow
  • gqeberha
  • Haifa
  • Heidelberg
  • Jerusalem
  • Johannesburg
  • Kazan
  • Krasnodar
  • League City
  • liasny
  • Lisboa
  • Los Angeles
  • Lyon
  • Maastricht
  • Madrid
  • Mainz
  • Milano
  • Montréal
  • Moscow
  • Moscow Oblast
  • Málaga
  • New York
  • Oxford
  • Palma
  • Philadelphia
  • Pisa
  • Porto
  • Pécs
  • Ramat Gan
  • Rio Grande do Sul
  • Rogers
  • Saint Petersburg
  • Salamanca
  • Santander
  • Sarajevo
  • Seattle
  • Seoul
  • Sevilla
  • Sioux City
  • Strovolos
  • Sutton
  • Tel Aviv-Yafo
  • Torrance
  • Ufa
  • València
  • Villejuif
  • Würzburg
  • Zagreb
Trial Identifier:

NCT01739764 2012-003144-80 GO28399

      Show trial locations

      The source of the below information is public registry websites such as,,, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to and/or and/or

      The below information is taken directly from public registry websites such as,,, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This open-label, multicenter, non-randomized study provided continued access to vemurafenib for eligible participants with BRAF V600 mutation-positive malignancy, who were previously enrolled and treated in an antecedent vemurafenib protocol and did not meet the protocol's criteria for disease progression, or were treated beyond progression and were still deriving clinical benefit (as assessed by investigator), and may have therefore potentially benefited from continued treatment with vemurafenib. Participants received treatment with oral vemurafenib at 960 milligrams (mg) twice daily (BID), 720 mg BID, or 480 mg BID, depending on the last dose in the antecedent protocol. Treatment continued until progression of disease or as long as the participant was deriving clinical benefit, as judged by the investigator (case-by-case decision with approval of the Medical Monitor), death, withdrawal of consent, unacceptable toxicity, loss to follow-up, or decision of the Sponsor to terminate the study, whichever occurred first.

      Hoffmann-La Roche Sponsor
      Phase 4 Phase
      NCT01739764,GO28399,2012-003144-80 Trial Identifier
      Vemurafenib Treatments
      Neoplasms Condition
      Official Title

      An Open-Label, Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol

      Eligibility Criteria

      All Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • BRAF V600 mutation-positive malignancy
      • Prior eligibility for and on study treatment from an antecedent vemurafenib protocol
      • Ability to begin treatment in the extension (rollover) protocol within 15 days following the last day of the study in the antecedent protocol
      • Female participants of childbearing potential and male participants with partners of childbearing potential must agree to use 2 adequate methods of contraception as defined by protocol during the course of this study and for at least 6 months after completion of study treatment
      Exclusion Criteria
      • Adverse event requiring discontinuation of vemurafenib in the antecedent protocol
      • Progressive disease during the antecedent protocol. If approval to treat beyond progression was already given in the antecedent protocol, the participant may roll over into the current protocol without sponsor approval. Under special circumstances, enrollment into this protocol and dosing beyond progression may be considered and will require approval of the sponsor

      Participants meeting any of the following exclusion criterion of the antecedent study at the time the participant is considered for the extension (rollover) study:

      • Current, recent (within 28 days prior to Day 1), or planned use of any antitumor therapy outside this study
      • Any other serious concomitant medical condition that, in the opinion of the investigator, would compromise the safety of the participant or compromise the participant's ability to participate in the study
      • History of malabsorption or other clinically significant metabolic dysfunction
      • History of clinically significant cardiac or pulmonary dysfunction as specified in antecedent study

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now